Skip to main content
. Author manuscript; available in PMC: 2014 Jun 10.
Published in final edited form as: Immunotherapy. 2011 Jun;3(6):789–801. doi: 10.2217/imt.11.68

Figure 2. Vaccination strategy targeting CD8 T-cell response against Toxoplasma.

Figure 2

Any vaccination strategy against Toxoplasma must involve appropriate selection of adjuvant and peptide pools such that there is optimal TCR–peptide MHC interaction (signal 1), costimulation (signal 2) and cytokine milieu (signal 3) during CD8 priming. In addition to peptide pool used, adjuvant selection may need to be altered depending on whether it is a prophylactic or therapeutic vaccine. Adjuvants that are highly inflammatory will result in preferential CD8 differentiation to effector lineage that may be ideal for therapeutic vaccination. Conversely, adjuvants that elicit comparatively lower inflammation will result in robust Tcm development, which may be optimal for prophylactic vaccination regimens. APC: Antigen-presenting cell; MPEC: Memory precursor effector cell; SLEC: Short-lived effector cell; Tem: T effector memory; Tcm: Central T memory; TCR: T-cell receptor.